| |
|
|
|
|
|
 |
| |
|
¿ÉÅׯ½Á¡¾È¾× [Proparacaine HCl]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
643901300[E00010181]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¼ö¿ë¼º Á¡¾È¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ °æ¿ìÀÇ ¾È°ú¿ë ±¹¼Ò¸¶ÃëÁ¦ : ´Ü½Ã°£ÀÇ °¢¸· ¸¶Ãë(¿¹: ¾È¾Ð ÃøÁ¤, ¿ì°¢°Ë»ç, °¢¸·ÀÇ ÀÌ ¹° ¹× ºÀÇÕ»ç Á¦°Å) ¹× °£´ÜÇÑ °¢¸· ¹× °á¸· óġ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1) ¾È¾ÐÃøÁ¤ ¹× À̹°¤ýºÀÇÕ»ç Á¦°Å : ¼ö¼úÀü 1-2¹æ¿ïÀ» Á¡¾ÈÇÑ´Ù.
2) °£´ÜÇÑ °¢¸· ¹× °á¸· óġ : 5-10ºÐ¸¶´Ù 1¹æ¿ïÀ» 5-7¹ø Á¡¾ÈÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
2) ¹Ì¼÷¾Æ ¹× ¿¡½ºÅ׸£Çü ±¹¼Ò¸¶ÃëÁ¦¸¦ ´ë»ç½ÃŰ´Â È¿¼Ò°è°¡ ¹Ì¼÷ÇÑ È¯ÀÚ.
|
| ½ÅÁßÅõ¿© |
1) ½ÉÁúȯ ȯÀÚ
2) °©»ó¼± ±â´ÉÇ×ÁøÁõ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¶§¶§·Î ÀϽÃÀûÀÎ Àڱذ¨, ÀÛ¿°¨, °á¸·È«Á¶°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ±Þ¼ºÀÇ °Ý½ÉÇÑ ±¤¹üÀ§ »óÇǼº °¢¸·¿°, »óÇǼ¼Æ÷ÀÇ ±«»ç¼º ºÎÀ°Çü¼º, °¢¸· Çʶó¸àÆ®, µ¥½º¸Þ¸·¿°À» µ¿¹ÝÇÑ È«Ã¤¿° µîÀ» Ư¡À¸·ÎÇÏ´Â ÁßÁõÀÇ ¾Ë·¹¸£±â¼º °¢¸·¹ÝÀÀÀÌ µå¹°°Ô ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼Õ°¡¶ô ³¡ÀÇ °ÇÁ¶ ¹× ±Õ¿À» µ¿¹ÝÇÏ´Â ¾Ë·¹¸£±â¼º Á¢Ã˼º ÇǺο°ÀÌ º¸°íµÇ¾ú´Ù.
4) ÇÁ·ÎÆÄ¶óÄ«ÀÎ ¿Ü¿ë ¾È°ú Á¦Á¦¿¡ ´ëÇÑ ¹®Çå¿¡¼ º¸°íµÈ ÀÌ»ó¹ÝÀÀÀº ¾Æ·¡¿Í °°´Ù.
| ºÐ·ù |
ÀÌ»ó¹ÝÀÀ |
| ¸é¿ª°è Àå¾Ö |
°ú¹Î¹ÝÀÀ |
| ½Å°æ°è Àå¾Ö |
½Ç½Å |
| ¾È°ú Àå¾Ö |
°¢¸· ¹Ì¶õ, °¢¸· ȥŹ, °¢¸·¿°, È帰 ½Ã¾ß, ±¤¼±°øÆ÷Áõ, »êµ¿, ¾È±¸ ÅëÁõ, ¾È±¸ ÀÚ±Ø, ¾È±¸ ºÎÁ¾, ¾È±¸ ºÒÆí°¨, ¾È±¸ ÃæÇ÷, ´«¹° ºÐºñ Áõ°¡ |
5) ¶ÇÇÑ, ¾à¹°ÀÇ ¿À¿ë ¶Ç´Â ³²¿ëÀº »óÇÇ¿¡ ´ëÇÑ ¸¶ÃëÀÇ µ¶¼º È¿°ú·Î ÀÎÇØ ¾È±¸ ¼Õ»óÀÌ À¯¹ßµÉ ¼ö ÀÖ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[Á¡¾È¾×] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Proparacaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability through the lipid layer of the nerve cell membrane. Proparacaine may alter epithelial sodium channels through interaction with channel protein residues. This limitation prevents the fundamental change necessary for the generation of the action potential.
|
| Pharmacology |
Proparacaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Proparacaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. More specifically, proparacaine appears to bind or antagonize the function of voltage gated sodium channels.
|
| Protein Binding |
Proparacaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Proparacaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Pharmacokinetics |
Proparacaine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : Á¡Àû ÈÄ 20ÃÊ À̳»
- ÀÛ¿ëÁö¼Ó½Ã°£ : 15-20ºÐ
|
| Biotransformation |
Proparacaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Plasma
|
| Toxicity |
Proparacaine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Proparacaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aminophylline Pentoxifylline increases the effect and toxicity of theophyllineDyphylline Pentoxifylline increases the effect and toxicity of theophyllineTheophylline Pentoxifylline increases the effect and toxicity of theophyllineOxtriphylline Pentoxifylline increases the effect and toxicity of theophyllineAnisindione Pentoxifylline increases the anticoagulant effectDicumarol Pentoxifylline increases the anticoagulant effectAcenocoumarol Pentoxifylline increases the anticoagulant effectWarfarin Pentoxifylline increases the anticoagulant effect
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Proparacaine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Proparacaine¿¡ ´ëÇÑ Description Á¤º¸ Proparacaine is a topical anesthetic drug of the amino ester group. It is available as its hydrochloride salt in ophthalmic solutions at a concentration of 0.5%. [Wikipedia]
|
| Dosage Form |
Proparacaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution Ophthalmic
|
| Drug Category |
Proparacaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anesthetics, LocalLocal Anesthetics
|
| Smiles String Canonical |
Proparacaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
|
| Smiles String Isomeric |
Proparacaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
|
| InChI Identifier |
Proparacaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
|
| Chemical IUPAC Name |
Proparacaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylaminoethyl 3-amino-4-propoxybenzoate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-03-15
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|